PrecivityAD2 is a blood test that helps doctors evaluate Alzheimer's disease alongside exams, history, and cognitive testing. On August 20, 2026, U.S. regulators cleared it for symptomatic adults age 40 and older, making it the first cleared Alzheimer's blood test available down to age 40.
The change matters because the test is an aid, not an answer by itself. According to C2N Diagnostics, federal labeling requires use with clinical assessment by professionals experienced in cognitive-impairment evaluation clearance announcement. Families still need a full workup, and the result guides what comes next.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What changed in 2026?
- How does the test fit an assessment?
- Why does age 40 matter for younger-onset families?
- Where does uncertainty remain?
What changed in 2026?
Two earlier Alzheimer's blood-test clearances applied only from age 55 upward. According to NeurologyLive, PrecivityAD2 extends that floor to age 40 for people with cognitive symptoms coverage of the clearance. That shift opens a blood-based option for younger adults who previously faced fewer cleared choices.
Clearance does not make the blood test a diagnosis on its own. The label calls for use in conjunction with standard clinical workup. A clinician with experience in cognitive impairment must interpret the score with symptoms, function, medications, and other causes.
How does the test fit an assessment?
The test measures plasma amyloid-beta 42/40 ratio and percent phosphorylated tau 217 with high-resolution mass spectrometry, WashU Medicine reports. Those values combine into an Amyloid Probability Score 2, reported as negative, positive, or likely positive. The score estimates the likelihood of brain amyloid linked to Alzheimer's.
In a 1,142-person study of people with cognitive symptoms, researchers compared the test against amyloid PET or spinal-fluid testing. According to NeurologyLive, the test showed 97.6% positive predictive value and 93.1% negative predictive value in that cohort coverage of the clearance. Strong values help doctors decide whether to confirm, watch, or look for another cause.
Why does age 40 matter for younger-onset families?
Younger-onset Alzheimer's affects people under 65, often in their 40s and 50s. The Alzheimer's Association reports that accurate diagnosis is frequently long and frustrating because symptoms are misattributed to stress, depression, or other conditions. Work problems, language slips, planning trouble, or mood change may be explained away for years.
A cleared blood option at 40 gives families a practical entry point to specialty evaluation. It does not replace careful history, neurologic examination, cognitive testing, or brain imaging when needed. It can make referral, counseling, and next-test decisions clearer and faster.
- Bring dated examples of memory, language, planning, or behavior change
- List medications, sleep problems, mood symptoms, and medical conditions
- Ask whether objective impairment is documented and what follow-up fits the score
- Ask who will explain results to work, family, and care plans
Where does uncertainty remain?
Scores near the cutoff carry less certainty. The intermediate likely-positive group made up about 17.3% of tested patients and had only 77.3% positive predictive value, NeurologyLive reports. For those patients, clinical correlation or PET or spinal-fluid follow-up remains important.
That limit fits wider guidance. The Alzheimer's Association issued its first specialty-care blood-biomarker guideline in July 2025, generally expecting about 90% sensitivity and specificity before replacing PET or spinal-fluid confirmation. Families should plan for a possible second test, a period of monitoring, or evaluation for non-Alzheimer's causes.
You Might Also Like
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: What Changed and What Comes Next for Younger-Onset Alzheimer’s Families
- Home-Based Dementia Care Research Priorities in 2026: What Changed and What Comes Next for Adult Children
- The HHS National Alzheimer’s Plan Update for 2026-2035: Coverage, Cost, and Access Questions for Adult Children
